|
|
Abstract Links |
|
Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson
JH, Dagnelie PC. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands. PURPOSE: In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life. In the present article, the effects of ATP on body composition, energy intake, and energy expenditure as secondary outcome measures in the same patients are reported. PATIENTS AND METHODS: Patients with NSCLC, stage IIIB or IV, were randomized to receive either 10 intravenous, 30-hour ATP infusions every 2 to 4 weeks or no ATP. Fat mass (FM), fat-free mass (FFM), and arm muscle area were assessed at 4-week intervals for 28 weeks. Food intake, body cell mass (BCM), and resting energy expenditure (REE) were assessed at 8-week intervals for 16 weeks. Between-group differences were tested for statistical significance by repeated-measures analysis of covariance. RESULTS: Fifty-eight patients were randomized (28 ATP, 30 control). No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001). Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004). No significant differences in REE between the ATP and control groups were observed. CONCLUSION: The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues. These effects are partly ascribed to maintenance of energy intake. 2006 TSI Health Sciences. Specifications | Research | Licensing | Where
to Buy | About
TSI | Contact
|
A Prospective, Randomized, Double Blind Study to Evaluate the Effects of Orally... A randomized, double-blind, placebo controlled triphosphate... Adenosine and cardioprotection in the diseased heart... Adenosine-mediated cardioprotection in the aging myocardium... Antihypertensive effect of all-cis-5,8,11,14,17... ATP flux through creatine kinase in the normal, stressed... ATP stimulates glucose transport through activation of P2... Beneficial effects of adenosine triphosphate on nutritional... Cardiovascular and pulmonary response to oral administration... Circulating ATP-induced vasodilatation overrides sympathetic... Clinical observation of oral adenosine triposthate in treating.... Diabetes mellitus and subjects' ageing: a study on the ATP... Effect of adenosine triphosphate and some derivatives on... Erythrocyte and the regulation of human skeletal muscle... Exogenous magnesium chloride-adenosine triphosphate... Impaired release of ATP from red blood cells of humans... Interstitial ATP and norepinephrine concentrations in... Intracoronary administration of adenosine triphosphate... Lung epithelial cells release ATP during ozone exposure... Measuring the contribution of pharmacological treatment... Mechanism of vasodilation to adenosine in coronary... Oxidative capacity and ageing in human muscle. Pretreatment of human myocardium with adenosine... Randomized clinical trial adenosine 5'-triphosphate... Reconditioning with ischemia or adenosine protects... Red blood cell regulation of microvascular tone through... Signaling pathways involved in adenosine triphosphate... Systemic hypoxia elevates skeletal muscle interstitia... The erythrocyte as a regulator of vascular tone. The hypotensive effect of docosahexaenoic acid... The T-tubule membrane ATP-operated P2X4 recepto...
|
Abstracts